Codagenix is a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies.
Codagenix uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors.
Codagenix was founded in 2012 by J. Robert Coleman and Steffen Mueller. The company is headquartered in Farmingdale, New York. Codagenix is a spun out of the laboratory of National Academy of Science Member Eckard Wimmer at Stony Brook University in 2012.
Codagenix's recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies.
Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses. It's algorithm, SAVE, designs viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells.
Codagenix is backed by Adjuvant Capital, Euclidean Capital, Topspin Partners,The Stony Brook University Center for Biotechnology and others. The company raised $20M in a Series B financing on Jan 13, 2020. This brings Codagenix's total funding to $38M to date.